These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20053764)

  • 1. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
    Sabnis G; Goloubeva O; Gilani R; Macedo L; Brodie A
    Mol Cancer Ther; 2010 Jan; 9(1):46-56. PubMed ID: 20053764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
    Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors and xenograft studies.
    Chumsri S; Sabnis GJ; Howes T; Brodie AM
    Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of selumetinib on the growth of anastrozole-resistant tumors.
    Sabnis GJ; Kazi A; Golubeva O; Shah P; Brodie A
    Breast Cancer Res Treat; 2013 Apr; 138(3):699-708. PubMed ID: 23508762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
    Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
    J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
    Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
    Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
    Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
    Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
    J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
    Brodie A; Njar V; Macedo LF; Vasaitis TS; Sabnis G
    Urol Oncol; 2009; 27(1):53-63. PubMed ID: 19111799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
    Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.